# Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic Targets

> **NIH NIH DP2** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $471,000

## Abstract

PROJECT SUMMARY
Hypertension is a major global health concern. In the U.S. alone, one-third of all adults have hypertension and
this rises to two-thirds by the age of 60. Hypertension is a key contributor to morbidity and mortality from
stroke, myocardial infarction, heart failure, peripheral vascular disease, and renal failure/dialysis. Unfortunately,
despite current treatment, blood pressure remains poorly controlled in approximately 50% of individuals with
this disease. Even when blood pressure is reasonably controlled, hypertension is associated with increased
cardiovascular risk. There is emerging evidence from our lab and others that this residual risk and the end-
organ effects of hypertension are largely mediated by inflammation. For example, mice that are deficient in T
cells, B cells, monocytes/macrophages, or one of a number of pro-inflammatory cytokines exhibit blunted
hypertension and reduced end-organ dysfunction in response to hypertensive stimuli. Yet most of these
studies have been conducted in experimental animals, particularly rodents, with limited studies examining the
effect of inflammation in human hypertension. Moreover, global or even partial immunosuppression in humans
is not without risk. To address this problem, the first goal of this proposal is to utilize a cutting-edge single cell
multiplex mass cytometry time of flight (CyTOF) approach to profile the immune cells in the peripheral blood of
normotensive and hypertensive humans to identify unique and possibly rare subpopulations that are altered in
human hypertension. In mass cytometry, antibodies to extracellular and intracellular targets are conjugated to
rare earth metal isotopes that are detected by a mass spectrometer. As obesity and aging are intricately
associated with hypertension, our study population will include people with a range of body mass indices and
age (35 to 75) to determine the extent to which observed hypertensive changes in immune profiles correlate
with obesity and aging. The second goal is to isolate these novel or altered cell populations through flow
sorting and further characterize them by RNA-sequencing, cytokine production, and/or deep sequencing of T
cell receptors in the case of T lymphocytes. Mapping the immunological landscape of hypertension, obesity,
and aging promises to lead to new diagnostic, prognostic, and therapeutic strategies to treat human
hypertension and limit the associated end-organ damage from this chronic, widespread disease without
inducing global immunosuppression.

## Key facts

- **NIH application ID:** 10000699
- **Project number:** 4DP2HL137166-02
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Meenakshi Swaminathan Madhur
- **Activity code:** DP2 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $471,000
- **Award type:** 4N
- **Project period:** 2021-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10000699

## Citation

> US National Institutes of Health, RePORTER application 10000699, Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic Targets (4DP2HL137166-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10000699. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*